Inovio Pharma (INO) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.16 --0%
EPS Growth %: +60.7%
Financial Fact:
Net loss: -20.76M
Today's EPS Names:
CRMT, PXED, AEHR, More
EPS Growth %: +60.7%
Financial Fact:
Net loss: -20.76M
Today's EPS Names:
CRMT, PXED, AEHR, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $1.74 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US big banks Q2 earnings preview: strong prints on tap amid market, economic strength
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Simulations Plus (SLP) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
